Treprostinil (Remodulin)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Pulmonary Arterial Hypertension

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
CA
  • REMODULIN (treprostinil) Injection is indicated for the long-term, subcutaneous or intravenous treatment of pulmonary arterial hypertension (PAH) in NYHA Class III and IV patients who did not respond adequately to conventional therapy. REMODULIN is a potent pulmonary and systemic vasodilator. Initiation of REMODULIN must be performed in a setting with adequate personnel and equipment for physiological monitoring and emergency care. REMODULIN is infused continuously through a subcutaneous or surgically placed indwelling central venous catheter.
Product first approved 2002Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Pulmonary Arterial Hypertension
NCT06350032 · AOP Orphan Pharmaceuticals AG
2024-07-31 – 2028-11 · Pulmonary Arterial Hypertension
What this study did
NCT04062565 · University of Arizona
2019-03-25 – 2025-12-31 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT01416636 · SciPharm SàRL
2009-03 – 2021-04 · Non-operable Chronic Thromboembolic Pulmonary Hypertension
What this study did
NCT02865733 · Shanghai Jiao Tong University School of Medicine
2016-08-01 – 2019-08-20 · Pulmonary Hypertension
What this study did
NCT00060996 · United Therapeutics
2003-02 – 2004-09 · Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT01884038 · United Therapeutics
2008-06 – 2010-06 · Liver Transplant
What this study did
NCT00067041 · United Therapeutics
2003-03 – 2003-12 · Peripheral Vascular Disease
What this study did
Phase 2 (2)
Pulmonary Arterial Hypertension
NCT03016468 · United Therapeutics
2017-05 – 2018-09 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT02261883 · United Therapeutics
2015-07-29 – 2023-05-17 · Persistent Pulmonary Hypertension of the Newborn
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT04005469 · Rhode Island Hospital
2020-11-13 – 2028-06-30 · Ischemia Reperfusion Injury, Delayed Graft Function
What this study did
NCT03654989 · University Hospital, Grenoble
2020-01-28 – 2021-12-07 · Diabetic Foot Ulcer
What this study did
Phase 1 (1)
Other / comorbidity
NCT05067270 · Eli Lilly and Company
2021-10-22 – 2021-12-06 · Type 1 Diabetes Mellitus
What this study did
Phase 4 (14)
Pulmonary Arterial Hypertension
NCT06317805 · AOP Orphan Pharmaceuticals AG
2023-12-06 – 2027-06-30 · Pulmonary Arterial Hypertension
What this study did
NCT06605326 · Guangzhou Institute of Respiratory Disease
2015-01-01 – 2024-09-01 · Pulmonary Hypertension, Pulmonary Arterial Hypertension, Chronic Lung Disease-Associated Pulmonary Hypertension, Lung Transplantation, Heart Failure
What this study did
NCT03497689 · United Therapeutics
2019-01-31 – 2022-05-11 · Pulmonary Arterial Hypertension
What this study did
NCT02882126 · United Therapeutics
2017-06 – 2021-06 · Pulmonary Arterial Hypertension
What this study did
NCT01615627 · Jewish General Hospital
2012-07-01 – 2019-02-28 · Pulmonary Arterial Hypertension
What this study did
NCT02893995 · United Therapeutics
2017-02 – 2018-04 · Pulmonary Arterial Hypertension
What this study did
NCT02847260 · United Therapeutics
2012-04 – 2014-03 · Pulmonary Arterial Hypertension
What this study did
NCT03055221 · United Therapeutics
2005-06-10 – 2014-02-25 · Pulmonary Arterial Hypertension
What this study did
NCT00439946 · United Therapeutics
2007-02 – 2011-03 · Pulmonary Arterial Hypertension
What this study did
NCT00494533 · United Therapeutics
2005-03 – 2005-10 · Pulmonary Arterial Hypertension
What this study did
NCT00058929 · United Therapeutics
2002-10 – 2005-08 · Pulmonary Arterial Hypertension, Pulmonary Hypertension
What this study did
Other / comorbidity
NCT00643604 · United Therapeutics
2008-03 – 2012-02 · Hypertension, Pulmonary
What this study did
NCT00373360 · United Therapeutics
2006-09 – 2008-01 · Pulmonary Hypertension
What this study did
NCT00458042 · United Therapeutics
2007-03 – 2007-11 · Hypertension, Pulmonary
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT01980979 · University of California, Los Angeles
2013-11 – 2015-12 · Congenital Heart Disease
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Treprostinil (Remodulin): this drugApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Ambrisentan (Letairis)ApprovedSmall moleculeEndothelin A receptorReliable signal
NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction
NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001).
Bosentan (Tracleer)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant)
NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults.
Epoprostenol (Flolan)
ApprovedUS marketing discontinued
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Macitentan (Opsumit)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier
Riociguat (Adempas)ApprovedSmall moleculeSoluble guanylate cyclaseReliable signal
NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5)
Sildenafil (Revatio)ApprovedSmall moleculePDE5Partial signal
NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001).
Sotatercept (Winrevair)ApprovedProtein / enzyme therapeuticActivin receptor type IIA (ActRIIA)Reliable signal
NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5)
NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025).
Tadalafil (Adcirca)ApprovedSmall moleculePDE5Weak signal
NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed
NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks.
Treprostinil (Orenitram)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49)
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5)
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Weak signalFeatured results are safety only in this race
Extended-Release Tacrolimus (VI-0106)Phase 3Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Imatinib Mesylate Prodrug (IkT-001Pro)Phase 3Small moleculePDGFR (imatinib-class)not yet gradedNo reviewed efficacy summary in this indication
RalinepagPhase 3Small moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001.
SeralutinibPhase 3Small moleculePDGFR/CSF1R/KIT (multi-kinase)Partial signal
NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Udenafil (Zydena)Phase 2/3Small moleculePDE5Weak signalNo reviewed efficacy summary in this indication
APL-9796Phase 2Monoclonal antibodyZIP12 (zinc transporter)not yet gradedNo reviewed efficacy summary in this indication
ROC-101Phase 2Small moleculeRho-associated kinase (ROCK, pan)not yet gradedNo reviewed efficacy summary in this indication
VasigrobartPhase 2Monoclonal antibodyPDGF-Bnot yet gradedNo reviewed efficacy summary in this indication
ZamicastatPhase 2Small moleculeDBHWeak signalNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
F230
—(overall)
Small moleculeEndothelin A receptornot yet gradedNo reviewed efficacy summary in this indication
GSK6792070
—(overall)
UndisclosedActivin signallingnot yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)Weak signal
NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1)
PF-07868489DiscontinuedProtein / enzyme therapeuticBone morphogenetic protein 9 (BMP9)Partial signalNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Treprostinil (Remodulin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Phase 4Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2027-06 · NCT06317805 · CT.gov ↗
What to watch
2028 (2)
June 2028 (1)
Phase 1/2Ischemia Reperfusion Injury, Delayed Graft FunctionRecruiting
Est. primary completion 2028-06-30 · NCT04005469 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2028-11 · NCT06350032 · CT.gov ↗
What to watch

See the full readout calendar ↗